What is CELL ESSENTIALS?
Established in 1998, Cell Essentials, Inc. operates as a Contract Research Organization (CRO) with a specialized focus on antibody production and advanced cell biology services. The company caters to a diverse clientele across diagnostics, drug discovery, and broader research initiatives. Key service offerings encompass custom hybridoma development, high-yield monoclonal antibody production, large-scale cell culture, and sophisticated cell-based assay development. Cell Essentials is committed to delivering scientific excellence and bespoke solutions, supporting projects ranging from small-scale research endeavors to extensive, large-scale life sciences undertakings.
How much funding has CELL ESSENTIALS raised?
CELL ESSENTIALS has raised a total of $61K across 1 funding round:
Debt
$61K
Debt (2021): $61K with participation from PPP
Key Investors in CELL ESSENTIALS
PPP
Public-Private Partnership
What's next for CELL ESSENTIALS?
The recent substantial expansion capital, alongside the company's significant Series B/C stage funding context, indicates a strategic push for scaling operations and potentially broadening its service portfolio. This investment is likely to fuel advancements in their antibody production capabilities and cell biology services, enabling Cell Essentials to enhance its support for drug discovery pipelines and diagnostic development. The company's trajectory suggests a focus on solidifying its market position as a premier CRO in the cell-related research domain, potentially exploring new technological integrations or expanding its client base globally.
See full CELL ESSENTIALS company page
